What Is Lu-177 PSMA Therapy?
Lu-177 PSMA therapy is a form of radioligand therapy that targets prostate cancer cells carrying the PSMA protein. PSMA (prostate-specific membrane antigen) is found in high amounts on most prostate cancer cells. In this therapy, a molecule designed to seek out PSMA is linked to Lutetium-177, a radioactive isotope that emits beta radiation. When injected into the bloodstream, this compound finds and binds to PSMA-positive cancer cells and delivers radiation directly to them.
The radiation travels only a short distance (a few millimetres), which means it primarily affects the cancer cells it has attached to while limiting damage to surrounding healthy tissue. This targeted approach is what distinguishes radioligand therapy from conventional external beam radiation, which irradiates a broader area.
The Theranostic Principle: Scan First, Then Treat
Before a patient receives Lu-177 PSMA therapy, a PSMA PET CT scan is performed. This scan confirms that the cancer cells express the PSMA target. If the scan shows strong PSMA uptake across the disease sites, it indicates that the therapy is likely to reach those cells effectively.
This two-step approach, where the same molecular target is used first for imaging and then for treatment, is called theranostics. It allows doctors to select patients who are most likely to benefit from the therapy and to avoid treating patients whose cancer does not express the target.
Who Is It For?
Lu-177 PSMA therapy is typically considered for patients with metastatic castration-resistant prostate cancer (mCRPC). This means the cancer has spread beyond the prostate and continues to progress despite hormone therapy. In most treatment protocols, Lu-177 PSMA therapy is offered after other standard treatments such as androgen receptor pathway inhibitors and chemotherapy have been tried.
The key eligibility criteria include a positive PSMA PET CT scan (showing that the cancer expresses PSMA), adequate kidney function, sufficient blood cell counts, and an overall health status that allows safe administration of the therapy. Your treating oncologist and nuclear medicine physician will assess these factors together.
What the Treatment Involves
The treatment is administered as an intravenous infusion. A calculated dose of Lu-177 PSMA is slowly injected through a vein, usually over about 30 minutes. The procedure itself is straightforward and does not require anaesthesia or surgical intervention.
Treatment is typically given in cycles, with each cycle spaced about 6 to 8 weeks apart. The number of cycles depends on how the patient responds and how well the treatment is tolerated. Blood tests and follow-up imaging are performed between cycles to monitor the response and check for any side effects.
Side Effects and Safety
Like any cancer treatment, Lu-177 PSMA therapy can cause side effects. The most commonly reported ones include fatigue, dry mouth (because salivary glands also express some PSMA), and temporary changes in blood cell counts. Nausea can occur but is usually mild.
Because the treatment involves radioactive material, patients receive instructions about radiation safety precautions after each cycle. These typically involve limiting close contact with others for a short period and following specific hygiene measures. The nuclear medicine team provides detailed guidance tailored to each patient’s situation.
Serious side effects are possible but less common. Regular monitoring through blood tests helps detect and manage any issues early.
How Effective Is It?
Clinical studies have shown that Lu-177 PSMA therapy can reduce PSA levels, shrink tumours, and improve quality of life in patients with advanced prostate cancer. The response varies from patient to patient, and not everyone experiences the same degree of benefit. Your doctor will discuss what the available evidence suggests for your specific situation.
It is important to understand that Lu-177 PSMA therapy is not described as a cure. It is a treatment option that can help control the disease and improve symptoms in appropriately selected patients.
Discussing Lu-177 PSMA Therapy with Your Doctor
If you have been diagnosed with advanced prostate cancer and are exploring treatment options, ask your oncologist whether a PSMA PET CT scan and Lu-177 PSMA therapy could be relevant to your case. The decision involves considering your disease stage, previous treatments, overall health, and the results of the PSMA scan.